Blar i NTNU Open på forfatter "Ghanima, Waleed Khalid"
-
Comparison of dabigatran, rivaroxaban and apixaban for effectiveness and safety in atrial fibrillation; a nationwide cohort study
Rutherford, Ole-Christian Walter; Jonasson, Christian; Ghanima, Waleed Khalid; Halvorsen, Sigrun (Peer reviewed; Journal article, 2020)The aim of this study was to compare the risk of stroke or systemic embolism (SE) and major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and apixaban in routine clinical practice. Methods ... -
Incidence of thrombotic complications in hospitalised and non-hospitalised patients after COVID-19 diagnosis
Tholin, Birgitte; Ghanima, Waleed Khalid; Einvik, Gunnar; Aarli, Bernt Bøgvald; Brønstad, Eivind; Skjønsberg, Ole Henning; Stavem, Knut (Peer reviewed; Journal article, 2021)Infection with coronavirus disease-2019 (COVID-19) may predispose for venous thromboembolism (VTE). There is wide variation in reported incidence rates of VTE in COVID-19, ranging from 3% to 85%. Therefore, the true incidence ... -
Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia – Follow-up of the RITP study
Tjønnfjord, Eirik; Holme, Pål Andre; Darne, Bernadette; Khelif, Abderrahim; Waage, Anders; Michel, Marc; Romdhan, Neila Ben; Ghanima, Waleed Khalid (Peer reviewed; Journal article, 2020)RITP was a double‐blind randomized, 78‐week follow‐up trial in which 109 adults with immune thrombocytopenias (ITP) who failed to achieve adequate response to steroids, were randomized to receive rituximab or placebo. Here, ... -
New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
Rutherford, Ole-Christian Walter; Jonasson, Christian; Ghanima, Waleed Khalid; Holst, René; Halvorsen, Sigrun (Journal article; Peer reviewed, 2018)Background Information is needed on bleeding risk factors specific for patients with atrial fibrillation (AF) treated with non-vitamin K oral anticoagulants (NOACs). We aimed to identify risk factors in a large real-world ... -
Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism
Hannevik, Trine-Lise; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege; Ahmed, Herish; Jacobsen, Eva-Marie; Quist-Paulsen, Petter; Porojnicu, Alina Carmen; Ree, Anne Hansen; Torfoss, Dag; Velle, Elin Osvik; Wik, Hilde Skuterud; Ghanima, Waleed Khalid; Sandset, Per Morten; Dahm, Anders Erik A (Peer reviewed; Journal article, 2020)Introduction: The direct oral anti-coagulants (DOAC) edoxaban and rivaroxaban are suggested treatment alternatives for cancer-associated venous thromboembolism (VTE) together with low molecular-weight heparins. New studies ...